Apply for AI Grants India

Why binding-affinity prediction matters

Drug–target binding affinity estimates how strongly a molecule interacts with a biological target. It is commonly expressed through measures such as Kd, Ki, or IC50. These values help teams compare compounds, prioritise experiments, and understand whether a chemical series is moving in the right direction.

AI can reduce the number of compounds that need to be synthesised and tested, but it does not replace experimental pharmacology. A useful model is a decision-support system: it ranks candidates, exposes uncertainty, and helps researchers spend laboratory time on the most informative experiments.

For Indian biotech startups, academic groups, and contract research organisations, this distinction is important. The strongest projects connect computational predictions to affordable, repeatable wet-lab validation rather than presenting a model score as proof of efficacy.

Define the prediction task first

Before selecting an algorithm, specify what the model must predict. Binding-affinity projects often fail because measurements from different assays are mixed without accounting for their context.

Clarify the following:

• Target definition: protein sequence, isoform, mutation, domain, or structure.
• Ligand definition: canonical SMILES, stereochemistry, salt form, tautomer, and protonation state.
• Endpoint: Kd, Ki, IC50, pIC50, or another assay-specific measure.
• Assay conditions: species, temperature, cofactors, cell-free versus cellular setting, and experimental method.
• Deployment goal: ranking new analogues, estimating a continuous value, classifying strong binders, or identifying off-targets.

Kd and Ki are not interchangeable with IC50. IC50 depends on assay conditions and substrate concentration, while equilibrium constants describe a different property. Convert values carefully, retain the original endpoint, and record the transformation in the dataset.

Assemble and clean the data

Start with public resources such as ChEMBL, BindingDB, PubChem, and structural repositories such as the Protein Data Bank. Supplement these with licensed datasets, internal assay results, and carefully documented literature extraction. The goal is not the largest possible table; it is a dataset with consistent definitions and traceable provenance.

A practical cleaning workflow should:

• Standardise units and transform affinity values consistently, often to pKd, pKi, or pIC50.
• Remove or flag duplicate measurements instead of silently averaging conflicting results.
• Normalise chemical structures while preserving stereochemistry and relevant protonation states.
• Separate assay types and experimental conditions where they are not comparable.
• Map target names to stable identifiers and distinguish isoforms and mutations.
• Track censored observations such as “greater than” or “less than” values.
• Keep source, publication, assay, and confidence metadata for every record.

This is where a reproducible scalable ML pipeline for predictive analytics becomes valuable. Version the raw data, cleaning code, feature-generation process, model, and evaluation split so that a result can be audited or reproduced months later.

Choose molecular and target representations

The representation determines what information the model can learn. Common options include:

• Fingerprints and descriptors: Morgan fingerprints, molecular weight, polarity, hydrogen-bond counts, rotatable bonds, and topological descriptors. These are fast and effective for baseline models.
• SMILES-based models: Transformers or recurrent architectures learn from tokenised molecular strings, though they can be sensitive to representation choices.
• Molecular graphs: Graph neural networks represent atoms as nodes and bonds as edges, allowing the model to learn local chemical relationships.
• Protein sequence embeddings: Useful when reliable structures are unavailable, particularly for target-family or mutation analysis.
• Structure-based features: Binding-pocket geometry, residue interactions, docking poses, and 3D grids can capture spatial information.

A strong first implementation usually combines a simple ligand baseline with a more expressive model. For example, compare a random forest or gradient-boosted model using fingerprints against a graph-based model using ligand and protein information. If the advanced model does not improve performance on a realistic holdout set, the issue may be data quality rather than architecture.

Build and validate the model

For labelled affinity data, supervised learning is the standard approach. Regression predicts a continuous affinity value; classification labels compounds such as active or inactive. Multi-task models can learn across related targets, but they require careful handling of missing labels and target similarity.

Validation must reflect the intended use. A random split can place near-identical analogues in both training and test sets, producing an optimistic result. Prefer:

• Scaffold splits to test chemically different compounds.
• Temporal splits to simulate prospective prediction using older data to predict newer experiments.
• Target-held-out splits when the goal is generalisation to new proteins.
• Clustered splits to prevent close molecular duplicates crossing partitions.

Report more than one metric. For regression, use RMSE, MAE, and correlation alongside calibration. For ranking, include enrichment factor, precision at the top-k threshold, and concordance measures. Always compare against simple baselines and report uncertainty, confidence intervals, and performance by target family or assay type.

External validation is the decisive step. Select a small batch of compounds prospectively, make predictions before testing, and compare the predicted ranking with laboratory results. This closes the loop between model development and experimental learning.

Use docking and physics-based methods carefully

Docking, molecular dynamics, free-energy calculations, and AI models serve different purposes. Docking can propose plausible poses and generate structural features, but docking scores are not reliable substitutes for measured affinity. Molecular dynamics may improve understanding of flexibility and stability, yet it can be computationally expensive and sensitive to setup choices.

A practical workflow is often hierarchical: use fast fingerprints or ligand-only models to screen a large library, apply structure-aware models to a smaller set, and reserve intensive simulations for the most promising candidates. Track the cost, turnaround time, and failure rate at each stage.

Make predictions useful to drug discovery teams

The output should be an experiment plan, not merely a leaderboard. For each candidate, provide:

• Predicted affinity and uncertainty range.
• Similar training compounds and whether the prediction is an extrapolation.
• Key molecular and protein features influencing the result.
• Potential liability signals such as poor solubility, reactivity, or selectivity concerns.
• Recommended next assay and the information it is expected to provide.

Use active learning to select compounds that balance predicted potency, chemical diversity, and uncertainty. This can produce more informative experiments than repeatedly choosing only the highest-scoring molecules. Link affinity predictions with ADME, toxicity, selectivity, and developability models; a strong binder is not automatically a viable drug candidate.

Teams building broader biomedical systems can also study AI for drug safety monitoring and reporting, because discovery and post-market evidence require compatible data governance, audit trails, and human review.

Key limitations and governance requirements

Affinity datasets contain publication bias, inconsistent assays, batch effects, and many measurements below or above detection limits. Models can also memorise chemical scaffolds, perform poorly on new targets, or encode artefacts from a particular laboratory. Explainability methods are useful for investigation, but feature importance is not proof of a binding mechanism.

For India-based projects, establish a data and governance plan early. Define ownership of experimental data, protect confidential structures, document software licences, and control access to patient-derived or clinical information. Maintain human oversight for decisions that affect clinical development. If a model supports regulated work, preserve validation records, model versions, and evidence that the system performs consistently under its stated conditions.

A practical implementation roadmap

1. Set the endpoint and use case. Decide whether the first release will rank analogues for one target or generalise across targets.
2. Create a trusted benchmark. Clean a narrow, well-documented dataset and establish scaffold and temporal baselines.
3. Train simple models first. Use fingerprints and tree-based methods before investing in complex architectures.
4. Add structure and protein context. Introduce docking, embeddings, or graph models only when they address a demonstrated limitation.
5. Validate prospectively. Predict a small compound panel, run experiments, and record failures as carefully as successes.
6. Automate reproducibility. Containerise feature generation and training, monitor data drift, and publish internal evaluation reports.
7. Integrate with laboratory operations. Connect predictions to compound registration, assay scheduling, and result capture.

The same principles used to operationalise other predictive systems—versioned data, monitoring, human review, and clear handoffs—are covered in guides to integrating predictive analytics into existing web applications.

FAQ

Is AI-predicted affinity the same as experimentally measured affinity?
No. It is an estimate with model- and data-dependent uncertainty. Experimental testing remains necessary.

Which model should a small team start with?
Begin with a fingerprint-based regression or classification baseline, a scaffold split, and a carefully curated dataset. Add graph or structure-based models after measuring a clear baseline gap.

Can AI predict binding for a completely new target?
Sometimes, but performance usually falls when the target or chemistry lies outside the training distribution. Protein similarity, structure quality, and uncertainty estimates matter.

What should a startup measure beyond accuracy?
Measure prospective hit rate, enrichment at the tested budget, experimental turnaround, cost per validated hit, and how often uncertainty correctly identifies risky predictions.

Support for Indian AI builders

A robust binding-affinity system combines chemistry, biology, machine learning, data engineering, and experimental design. Indian founders and research teams developing such tools can explore support through AI Grants India, especially when the project has a defined validation partner, responsible data plan, and measurable healthcare impact.